Argus Trims Zoetis (ZTS) Price Target to $190, Keeps Constructive View

Zoetis Inc. (NYSE:ZTS) is one of the high-margin pharma stocks to buy now. Argus has trimmed its price target on Zoetis Inc. (NYSE: ZTS) to $190 from $200, maintaining a cautious but constructive view on the animal health giant. While the firm did not change its overall outlook, the revised target reflects a more tempered near-term assessment of valuation and broader market conditions.

A veterinarian administering a vaccine to a herd of cattle in a farm.

Zoetis, a global leader in veterinary pharmaceuticals and diagnostics, has faced mixed investor sentiment in recent months. Although the company continues to deliver steady growth through its companion animal segment and expanding international footprint, pockets of weakness in livestock-related markets and currency headwinds have pressured earnings expectations.

Argus’ adjustment comes as analysts across the Street maintain generally favorable views on Zoetis. The stock holds an average rating of Overweight, underscoring confidence in its long-term positioning. Investors are watching closely for updates on pipeline innovation and regulatory approvals, which could help reignite momentum.

Despite the reduced price target, Argus emphasized that Zoetis remains well capitalized and strategically focused, with an attractive portfolio that spans vaccines, parasiticides, and diagnostics. The firm sees upside potential as underlying demand trends in pet care normalize and input cost pressures begin to ease. Zoetis shares have been relatively stable year to date, reflecting the broader defensiveness of the animal health sector.

READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Best Industrial Automation Stocks to Buy for the Next Decade

Disclosure: None. This article is originally published at Insider Monkey.